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ABSTRACT
Cancer progression is characterized by a complex reciprocity between neoplastic 
epithelium and adjacent stromal cells. In ductal carcinoma in situ (DCIS) of the breast, 
both reduced stromal decorin expression and myxoid stroma are correlated with 
increased recurrence risk. In this study, we aimed to investigate paracrine regulation 
of expression of decorin and related extracellular matrix (ECM) proteins in cancer-
associated fibroblasts (CAFs). Transforming growth factor-β1 (TGF-β1) was identified 
as a competent ECM modulator, as it reduced decorin and strongly enhanced versican, 
biglycan and type I collagen expression. Similar but less pronounced effects were 
observed when fibroblasts were treated with basic fibroblast growth factor (bFGF). 
Despite this concerted ECM modulation, TGF-β1 and bFGF differentially regulated 
alpha-smooth muscle actin (α-SMA) expression, which is often proposed as a CAF-
marker. Cancer cell-derived secretomes induced versican and biglycan expression in 
fibroblasts. Immunohistochemistry on twenty DCIS specimens showed a trend toward 
periductal versican overexpression in DCIS with myxoid stroma. Cancer cell adhesion 
was inhibited by decorin, but not by CAF-derived matrices. Cancer cells presented 
significantly enhanced spreading when seeded on matrices derived from TGF-β1-
treated CAF. Altogether these data indicate that preinvasive cancerous lesions might 
modulate the composition of surrounding stroma through TGF-β1 release to obtain 
an invasion-permissive microenvironment.
INTRODUCTION 
The significance of the tumor microenvironment in 
cancer progression has been increasingly acknowledged. 
Cancer progression is the result of complex cross-talk 
between neoplastic cells and neighbouring stromal cells, 
such as fibroblasts, endothelial cells, adipocytes and 
inflammatory cells [1, 2]. Gene expression profiling of 
neoplastic epithelium and stroma during breast cancer 
progression revealed that the expression of molecules 
involved in extracellular matrix (ECM) remodeling is 
altered during the transition from ductal carcinoma in 
situ (DCIS) to invasive ductal carcinoma (IDC) [3-6]. 
Extensive stromal gene expression alterations also occur 
during the transition from normal breast to DCIS [4]. 
Gevaert et al. reported overexpression of the small leucin-
rich proteoglycans (SLRP) decorin and fibromodulin 
in a gene expression signature associated with good 
Oncoscience635www.impactjournals.com/oncoscience
prognosis in invasive breast cancer [7]. Decreased stromal 
decorin and lumican correlated with worse prognosis 
in lymph node-negative invasive breast cancer [8]. 
Immunohistochemical (IHC) analysis showed that stromal 
decorin expression is highest in normal breast tissue, 
lower in DCIS and lowest in IDC [9]. A similar trend 
was noticed in the colon, with strong decorin expression 
in normal tissue, hyperplastic adenomas and the majority 
of tubular adenomas, and decreased decorin expression in 
tubulo-villous adenomas and most adenocarcinomas [10].
We recently observed that decreased periductal 
decorin immunoreactivity correlated with the presence of 
myxoid stromal architecture in DCIS. Reduced stromal 
decorin and myxoid stroma were both significantly 
associated with an increased recurrence risk in DCIS [11]. 
As not all DCIS will evolve to IDC, stromal alterations 
might enable the identification of lesions that possess the 
capability to progress. We hypothesized that decreased 
stromal decorin may contribute to the pathogenesis of 
myxoid stroma, as decorin seems to play an important role 
in collagen fibrillogenesis [12]. Myxoid stroma and the 
associated decorin reduction might mirror the propensity 
of some DCIS lesions to progress to IDC. Neoplastic 
lesions may induce ECM alterations through paracrine 
corruption of fibroblasts, resulting in an invasion- 
permissive stroma. In this study, we aimed to investigate 
paracrine regulation of stromal decorin expression, as 
well as related ECM protein expression. Immortalized 
CAF were used as an in vitro model. In vitro findings 
were translated to the clinical setting by performing IHC 
on DCIS specimens. In addition, we investigated the 
effect of decorin and CAF-derived matrices on cancer cell 
adhesion. The main goal of this study was to gain more 
insight in cancer-induced changes in the peritumoral ECM, 
since this might aid the identification of new therapeutic 
targets, as well as novel prognostic markers.
RESULTS
TGF-β1 and bFGF suppress decorin expression at 
the protein level
We screened ten cytokines for the differential 
regulation of decorin expression in CAFs. TGF-β1 
Figure 1: Cytokine treatment influences ECM protein expression in CAFs. (A) Western blot showing the effect of treatment 
of CAFs with ten different growth factors (all at a concentration of 10 ng/ml) on the expression of decorin and α-SMA. Tubulin was used 
as a loading control. (B) Western blot illustrating the effect of three different concentrations of TGF-β1, bFGF or EGF on the expression of 
decorin and α-SMA in CAFs. Tubulin was used as a loading control. (C) Table displaying the normalized mRNA expression profile of five 
SLRP’s, two hyalectans, type 1 collagen and α-SMA in CAFs after treatment with bFGF, EGF or TGF-β1, either alone or in combination 
(10 ng/ml). Red and blue color scales represent 2-, 5- and 10-fold up- and downregulation, respectively. Values are mean ± SD and represent 
3 independent experiments.
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and bFGF were the strongest suppressors of decorin 
expression, followed by TNF-α, TGF-α1 and EGF (Figure 
1A). TGF-β1 and bFGF treatment resulted in 10-fold 
and 5-fold downregulation, respectively. Additionally, 
we assessed the effect of these cytokines on α-SMA 
expression, as this molecule is often presented as a CAF-
marker [13-15]. Expression of α-SMA in CAFs was 
8-fold upregulated by TGF-β1, whereas bFGF, EGF and 
TGF-α1 completely suppressed α-SMA expression, as 
previously observed [15, 16]. The differential regulation of 
α-SMA and decorin prompted us to select bFGF, EGF and 
TGF-β1 for further experiments. Next, CAFs were treated 
with bFGF, EGF and TGF-β1 in three concentrations. 
Downregulation of decorin expression was only observed 
when cells were treated with the highest concentration 
of 10 ng/ml (Figure 1B). A concentration of 1 ng/ml 
bFGF, EGF or TGF-β1 exerted distinct effects on α-SMA 
expression, and these were magnified by increasing the 
concentration to 10 ng/ml. Therefore, we selected the 
latter for subsequent experiments.
TGF-β1 and bFGF differentially modulate ECM 
protein expression
CAFs were treated with bFGF, EGF and TGF-β1 at 
10 ng/ml, either alone or in combination. RT-qPCR was 
performed to assess the mRNA expression of ACTA2, 
COL1A1, five SLRP’s (ASPN, BGN, DCN, FMOD, LUM) 
and two hyalectans (VCAN and ACAN). EGF did not exert 
significant effects on mRNA expression (Figure 1C). 
ACTA2 was about 4-fold downregulated by bFGF and >6-
fold upregulated by TGF-β1. When bFGF and TGF-β1 
were combined, the stimulatory TGF-β1 effect was almost 
completely counteracted by bFGF, while EGF was not 
able to neutralize this TGF-β1 effect (Figure 1C).
BGN and VCAN displayed a similar mRNA 
expression pattern: both were strongly induced by TGF-β1, 
and this was enhanced by bFGF, resulting in a >15-fold 
upregulation of BGN and a >100-fold upregulation of 
VCAN (Figure 1C). COL1A1 expression was almost 10-
fold induced by TGF-β1, though this was attenuated by 
bFGF. ASPN expression was 3-fold stimulated by TGF-β1, 
but bFGF did not significantly influence its expression. 
Three other SLRP’s were expressed alike: DCN, FMOD 
and LUM were all downregulated by bFGF and this effect 
was enhanced by TGF-β1. ACAN, a hyalectan, was 4-fold 
upregulated by TGF-β1 but this effect was attenuated 
by EGF, whereas the combination of bFGF and TGF-β1 
caused a 3-fold downregulation. Altogether, these findings 
point to differential regulation of ECM proteins, with 
upregulation of versican, biglycan, COL1A1 and α-SMA 
as a signature of TGF-β1-induced protein expression. This 
experiment was repeated to confirm the aforementioned 
RT-qPCR results at the protein level by Western blotting. 
TGF-β1 strongly induced versican, biglycan and α-SMA, 
and caused downregulation of decorin in fibroblasts. 
Similar to the RT-qPCR findings, bFGF treatment only 
had a moderate effect on the upregulation of versican 
and biglycan, whereas it effectively suppressed decorin 
and α-SMA expression. When bFGF was combined 
with TGF-β1, the stimulatory TGF-β1 effect on α-SMA 
expression was clearly attenuated, whereas decorin 
downregulation and biglycan and versican upregulation 
were enhanced (Figure 2A).
Cancer cell-derived secretomes affect ECM 
protein expression in CAFs
Conditioned medium (CM) was collected from 
six breast cancer cell lines and four colorectal cancer 
Figure 2: Treatment of CAFs with combined cytokines 
or cancer cell-derived secretomes affects ECM protein 
expression. (A) Western blot showing the effects of bFGF, 
EGF and TGF-β1 treatment (10 ng/ml) on the expression of 
biglycan, decorin, α-SMA and versican in CAFs. (B) Western 
blot illustrating the effects of treatment with cancer cell-derived 
conditioned medium (CM) on the expression of biglycan, 
decorin, α-SMA and versican in CAFs. TGF-β1 treatment (1 and 
10 ng/ml) was included as a positive control. Tubulin was used 
as loading control (A, B).
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cell lines. CAFs were treated with this CM for 6 days. 
Fibroblasts treated with TGF-β1 (1 and 10 ng/ml) were 
included as a positive control (Figure 2B). Although CM 
of almost every cancer cell line caused a slight to moderate 
upregulation of α-SMA, CM of MDA-MB-231 caused a 
distinct increase in α-SMA expression. Simultaneously, it 
was the most potent suppressor of decorin expression and 
the strongest inducer of biglycan and versican. CM of all 
breast and colorectal cancer cell lines enhanced versican 
and biglycan expression. SKBR3 was the only other breast 
cancer cell line of which CM downregulated decorin. 
Remarkably, CM of all colorectal cancer cell lines caused 
increased decorin expression, but presently we cannot 
explain this differential regulation.
Immunohistochemical evaluation of ECM protein 
expression
Since we previously reported a significant 
association between periductal myxoid stroma and reduced 
stromal decorin in DCIS [11], we aimed to investigate 
whether a correlation existed between myxoid stroma 
and increased biglycan and versican immunoreactivity. 
IHC was performed on eight myxoid DCIS, and twelve 
DCIS with sclerotic stroma. In DCIS with low stromal 
versican, 3 of 11 (27%) lesions presented myxoid stroma, 
while DCIS with high stromal versican counted 5 of 8 
(63%) myxoid cases (Figure 3A-B). Despite this trend, 
statistical significance was not reached (p=0.181), which 
is likely due to lack of power. Calculated power amounted 
only 0.197 (β=0.803). Stromal biglycan expression was 
not able to discern myxoid from sclerotic DCIS (Figure 
3C-D): in DCIS with low to moderate stromal biglycan, 
7 of 14 (50%) DCIS presented myxoid stroma, while 1 
of 6 DCIS (17%) with high stromal biglycan had myxoid 
stroma (p=0.325) (Figure 4).
Decorin negatively influences cancer cell adhesion
In addition to paracrine regulation of stromal protein 
expression, we aimed to investigate the effects of decorin 
on cancer cell adhesion. Human recombinant His-tagged 
decorin was purified from CM of decorin-overexpressing 
HEK-293-EBNA-DCN cells. Western blotting confirmed 
purification of both His-tagged core protein (50 kDa) and 
glycosylated decorin (75-160 kDa). As a quality control, 
purified decorin was incubated with chondroitinase ABC, 
a chondroitin and dermatan sulphate degrading enzyme 
[17]. After digestion, Western blotting showed that only 
His-tagged core protein remained (results not shown).
Three colorectal cancer cell lines (CaCo-2, HCT8/
E11 and SW480) and three breast cancer cell lines (BT474, 
SKBR3 and T47D) were seeded onto coatings of purified 
decorin in different concentrations, or type I collagen (10 
µg/ml in PBS). Multiple cell lines were used to exclude 
a cell line specific effect. Experiments were performed 
Figure 3: Comparison of stromal versican and biglycan expression in DCIS lesions with sclerotic or myxoid stroma. 
(A) Bar chart displaying the relation between stromal versican expression and stromal architecture. Despite a trend toward high 
versican expression in DCIS with myxoid stroma, statistical significance was not reached (p=0.181), due to lack of power (β=0.803). 
(B) Photomicrograph displaying high periductal versican immunoreactivity (arrow) in a DCIS lesion with myxoid stroma. Original 
magnification 100x. (C) Bar chart illustrating the absence of any association (p=0.325) between stromal biglycan expression and stromal 
architecture. (D) Photomicrograph illustrating high periductal biglycan staining (arrow) in a DCIS lesion with myxoid stroma. Original 
magnification 100x.
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in duplicate, to quantify adhesion by SRB staining and 
to assess effects of the coatings on cell metabolism 
by MTT assays. Collagen coatings did not affect cell 
adhesion as compared with PBS control (Figure 5A-D), 
but significantly increased metabolic activity in CaCo-2 
cells was observed (p=0.015). Decorin coatings inhibited 
attachment of all cell lines in a dose-dependent manner. 
This anti-adhesive effect was statistically significant when 
a concentration of 5 µg/ml decorin was used (p≤0.007 
for all cell lines) and was even more distinct with 10 
µg/ml decorin (p≤0.002 for all cell lines). Altogether, 
these findings indicate that cancer cells attach to type I 
collagen, but they are not able to attach to decorin as a 
single substrate.
We wondered whether decorin exerted anti-adhesive 
effects in the presence of type I collagen. Experiments 
were repeated with combined coatings, containing 10 µg/
ml type I collagen and varying amounts of purified decorin 
(range 1-20 µg/ml). When cell adhesion was assessed by 
SRB assay, BT474 and HCT8/E11 were the only cell lines 
of which adhesion was significantly decreased when 20 
µg/ml decorin was added to the coating (p<0.001 and 
p=0.030, respectively). BT474 was the only cancer cell 
line of which the metabolism significantly diminished 
when 5 µg/ml decorin or more was added to the type 
I collagen coating (p<0.001). The highest decorin 
Figure 4: Immunohistochemical staining of stromal protein expression in DCIS with sclerotic or myxoid stroma. 
Microphotographs displaying HE staining (A-B), and IHC staining for biglycan (C-D), decorin (E-F) and versican (G-H). Panels A-C-
E-G display photographs of one DCIS lesion with sclerotic stroma; panels B-D-F-H display one DCIS lesion with myxoid stroma. This 
figure illustrates that myxoid DCIS present reduced periductal decorin staining and tend to have increased periductal versican and biglycan 
expression, whereas sclerotic DCIS generally present strong stromal decorin immunoreactivity, and tend to lack stromal versican and 
biglycan. Original magnification 100x.
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concentration of 20 µg/ml also decreased cell metabolism 
in SKBR3 (p=0.010), T47D (p=0.020), CaCo-2 (p=0.009) 
and HCT8/E11 (p<0.001). Overall, type I collagen clearly 
counteracted the anti-adhesive effect of decorin (Figure 
5 E-H).
In addition, cell adhesion was assessed by an 
electrical impedance assay (Figure 6). BT474 and CaCo-2 
cells were seeded onto coatings containing decorin, type I 
collagen or both. Decorin significantly inhibited adhesion 
in these cell lines (p=0.001 for both) compared with 
control coatings. Pure type I collagen coatings significantly 
enhanced adhesion of CaCo-2 cells compared with control 
coatings (p=0.001) or collagen/decorin coatings (p=0.021). 
Type I collagen coatings exerted an early stimulatory 
effect on adhesion of BT474 cells compared with control 
coatings, which caused a significant difference between 
Figure 5: SRB and MTT adhesion assays with cancer cells seeded onto coatings containing type I collagen and decorin. 
(A-D) Bar charts displaying the effect of pure decorin coatings and a type I collagen coating on cancer cell adhesion, as measured by MTT 
(A,C) and SRB (B,D) assays. (E-H) Bar charts illustrating the effect of different concentrations of decorin on cancer cell adhesion when 
added to a type I collagen coating (10 µg/ml in PBS), as measured by MTT (E,G) and SRB (F,H) assays. All experiments were performed 
with three breast and three colorectal cancer cell lines, to exclude a cell line specific effect. Results are presented from five wells per assay 
from three independent experiments. Values are mean percentage ± SD. ° p<0.05 and * p<0.001 as compared with control. Col: type I 
collagen; DCN: decorin.
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the slopes of both curves (p=0.001). Addition of decorin 
to the type I collagen coating slightly diminished the cell 
index of BT474 cells, but did not affect the slope of the 
curve (p=0.834).
CAF-derived matrices
In addition to adhesion assays on single or dual 
reagent coatings, we attempted to mimic the in vivo 
situation by seeding cancer cells on CAF-derived matrices. 
Matrices were prepared as described by Castello-Cros 
et al., [18] and CAFs were treated six days with bFGF, 
TGF-β1 or both. After CAF removal, the remaining 
matrices were coated with decorin (20 or 50 µg/ml) or 
PBS control. Cancer cells were seeded onto matrices with 
or without decorin coating, and MTT and SRB adhesion 
assays were carried out after 24h incubation. These 
adhesion assays revealed no significant differences in cell 
adhesion (Figures 7-8). Moreover, application of decorin 
coatings on the matrices did not significantly inhibit 
adhesion, which is in line with the adhesion assays with 
combined coatings, where type I collagen counteracted 
the anti-adhesive effect of decorin. As CAFs produce 
type I collagen [19], a sufficient amount was present to 
neutralize the applied decorin coating.
However, phase-contrast microscopic analysis 
revealed morphological differences in the way cancer cells 
adhered to different matrices. SW480 cells, representative 
for colorectal cancer cells, and T47D, representative 
for breast cancer cells, are shown in Figure 7C and 8C, 
respectively. Cancer cells seeded on matrices derived 
from TGF-β1-treated fibroblasts seemed to attach along 
preformed ‘tracks’, compared with the random adhesion 
pattern of cells seeded on matrices from untreated or 
bFGF-treated CAFs. This phenomenon was most distinct 
with SW480 cells, which was probably due to their 
mesenchymal aspect: most SW480 cells are already 
spindle-shaped and therefore their uniform orientation 
was more obvious. We excluded that this phenomenon 
was due to TGF-β1 remnants in the matrices, by seeding 
TGF-β1-treated (1 µg/ml) cancer cells on matrices from 
untreated fibroblasts. All cell lines adhered in the same 
random pattern as cancer cells seeded on control matrices 
without TGF-β1 (results not shown).
The rate of cancer cell spreading was quantified 
by determining the factor shape of twenty cells on each 
matrix (Figure 9). This was not possible for the BT474 and 
CaCo-2 cell lines, as these grow in dense islands in which 
separate cells cannot be distinguished. SW480 and T47D 
cancer cells presented enhanced spreading when seeded on 
matrices from TGF-β1-treated CAFs, which is reflected by 
the significantly altered cell shapes (p=0.010 and p=0.046, 
respectively). There was a trend toward increased cell 
spreading when seeded on matrices of bFGF/TGF-β1-
treated CAFs, though not statistically significant. HCT8/
E11 cells showed a trend towards enhanced cell spreading 
on matrices from TGF-β1-treated CAFs, and distinct 
alterations on matrices from bFGF/TGF-β1-treated 
CAFs (p<0.001). SKBR3 cells displayed only limited, 
statistically non-significant alterations in cell spreading 
and factor shape. Although some SKBR3 cells displayed 
a more irregular shape, the majority retained its epitheloid 
morphology (Figure 9D). Altogether, the results of these 
experiments indicate that TGF-β1-induced modulation of 
the tumor microenvironment affects cancer cell spreading 
but not adhesion.
DISCUSSION
The ECM undergoes many alterations which support 
expansion and invasion of tumors [2, 13]. Such alterations 
are reflected in the stromal architecture of DCIS of the 
breast, since we recently observed that the presence of 
periductal myxoid stroma is a potential prognostic marker 
Figure 6: Real-time monitoring of cancer cell adhesion 
on decorin and type I collagen coatings. Real-time 
monitoring of cell adhesion of BT474 (A) and CaCo-2 (B) cells 
by measuring electrical impedance during 24h. The cell index, 
i.e. the change in electrical impedance, is displayed in function 
of time (in hours) as mean ± SD. Cells were seeded on coatings 
containing PBS only (blue), type I collagen (green), decorin 
(red) or type I collagen combined with decorin (purple).
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Figure 7: Adhesion assays with SW480 cells seeded onto CAF-derived matrices. SW480 cells were seeded onto CAF-derived 
matrices with or without decorin coating, and cell adhesion was measured by MTT (A) and SRB (B) assay after 24 hours. Results are 
presented from three wells per assay from two independent experiments. Values are mean percentage ± SD. CAFs that produced the 
matrices were treated either with vehicle control, bFGF, TGF-β1 or both cytokines. (C) When seeded on matrices derived from TGF-β1-
treated CAFs, elongated SW480 cells adhered in a highly organized fashion along preformed ‘tracks’ in the matrices, whereas the control 
or bFGF treatment showed a rather random distribution of the cells. Scale bar: 200 µm.
Figure 8: Adhesion assays with T47D cells seeded onto CAF-derived matrices. T47D cells were seeded onto CAF-derived 
matrices with or without decorin coating, and cell adhesion was measured by MTT (A) and SRB (B) assay after 24 hours. Results are 
presented from three wells per assay from two independent experiments. Values are mean percentage ± SD. CAFs that produced the 
matrices were treated either with vehicle control, bFGF, TGF-β1 or both cytokines. (C) When seeded on matrices derived from TGF-β1-
treated CAFs, T47D cells adhered in an organized fashion along preformed ‘tracks’ in the matrices, whereas the control or bFGF treatment 
showed a rather random distribution of the cells, with formation of more and larger cellular islands. Scale bar: 200 µm.
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for increased recurrence risk in DCIS [11]. Myxoid stroma 
was strongly associated with reduced stromal decorin 
expression [11]. As decorin plays an important role in 
the assembly of collagen fibrils [12], decreased stromal 
decorin may contribute to the development of myxoid 
stroma. In this study, we identified TGF-β1 and bFGF as 
potent decorin suppressors in CAFs. In addition, TGF-β1 
demonstrated to be an overall powerful ECM modulator, 
as it strongly upregulated type I collagen, versican and 
biglycan. Similar effects, though less pronounced, were 
observed by treating CAFs with bFGF or cancer-cell 
derived CM.
Expression of α-SMA was differentially regulated by 
TGF-β1 and bFGF: both cytokines downregulated decorin 
and upregulated versican, whereas α-SMA was induced 
by the former and suppressed by the latter, in accordance 
with previous studies [15, 16]. This might explain the 
previously reported lack of correlation between myxoid 
stroma and stromal α-SMA expression in DCIS, despite 
the distinct association between stromal architecture 
and decorin expression [11]. It would be of interest to 
determine if versican is a more robust CAF marker than 
α-SMA. As bFGF downregulates α-SMA but induces 
versican, some CAFs might be α-SMA-negative but 
versican-positive, depending on the predominant cytokine 
production by adjacent neoplastic cells. Nevertheless, 
secretome experiments show that nearly all breast and 
colorectal cancer cell lines induce both α-SMA, versican 
and biglycan in CAFs, which implies TGF-β1-like effects. 
Similar observations were reported by others. Co-cultures 
of CaCo-2 or HT29 cells with canine mammary stromal 
cells resulted in TGF-β1-induced versican expression 
[20]. Coulson-Thomas et al. observed that direct cell-cell 
contact of CaCo-2 or HCT116 with fibroblasts induced 
Figure 9: Quantification of cancer cell spreading on CAF-derived matrices. Box plots illustrating the extent of cell spreading 
of SW480 (A), T47D (B), HCT8/E11 (C) and SKBR3 (D) cells on matrices as quantified by factor shape (= inverse circularity or P2/4πA). 
Matrices are derived from untreated CAFs and CAFs treated with bFGF, TGF-β1 or both. When seeded on matrices from TGF-β1-treated 
CAFs, SW480 and T47D cancer cells presented enhanced spreading, which is mirrored by the significantly altered cell shapes. HCT8/
E11 cells showed a trend towards enhanced cell spreading on matrices from TGF-β1-treated CAFs, and significant alterations on matrices 
from bFGF/TGF-β1-treated CAFs. SKBR3 cells displayed only limited, statistically non-significant alterations in cell spreading and factor 
shape. N.S.= non-significant (p>0.05); circles = outliers; squares = extremes.
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an increased expression of collagens and biglycan in 
the latter [21]. TGF-β1 and CM from pancreatic cancer 
cells synergistically suppressed decorin and lumican, and 
stimulated versican expression in pancreatic stellate cells 
[22]. CM of all colorectal cancer cell lines upregulated 
decorin expression, while CM of the majority of the 
breast cancer cell lines caused decorin suppression. We 
speculate that TGF-β1-induced decorin downregulation 
is counteracted by another, presently unknown, ligand 
in colorectal cancer CM. Despite this finding, stromal 
decorin seems to be consistently downregulated in 
different types of cancer compared with normal tissue, as 
demonstrated by Bozoky et al. [23]. Decrease of stromal 
decorin during colorectal and breast cancer progression 
has also been shown by others [9, 10].
Stromal biglycan expression was not related to 
stromal architecture, but a trend was noted for stromal 
versican expression, as myxoid DCIS displayed twice as 
often increased versican immunoreactivity. Various studies 
have demonstrated increased stromal versican expression 
in tumors compared with normal tissue, such as in cancer 
of prostate, breast, colon, pancreas and ovary [22, 24-28]. 
Versican formed part of a 74-gene profile that classified 
IDC and DCIS, and revealed to be upregulated in IDC [6]. 
Canavese et al. studied versican in a DCIS cohort without 
available outcome data [29]. Stromal versican expression 
defined a specific subtype of DCIS, characterized by 
high nuclear grade and often presenting comedonecrosis 
[29]. We speculate that the majority of DCIS with high 
periductal versican will also present myxoid stroma 
and reduced decorin expression, and patients with such 
lesions may be more likely to relapse. Stromal versican 
overexpression has been investigated in patients with 
node-negative invasive breast cancer and was associated 
with reduced relapse-free survival [30, 31]. In colorectal 
cancer, upregulated biglycan expression was associated 
with an increased risk of both lymph node and distant 
metastasis [32]. Future research on large patient cohorts 
is warranted to explore the value of stromal versican and 
biglycan expression as a prognostic marker for recurrence 
in DCIS.
In addition, we investigated the influence of 
decorin on cancer cell adhesion. Decorin effectively 
inhibited adhesion of both breast and colorectal 
cancer cells, although this was counteracted by type 
I collagen. According to Kenny et al., ovarian cancer 
cells preferentially adhere to and invade type I collagen 
[33]. As the mammary stroma contains more than just 
decorin and type I collagen, we attempted to mimic the 
in vivo situation by preparing CAF-derived matrices [18]. 
Consequently, matrices from TGF-β1-treated CAFs hold 
higher versican and biglycan levels and lower decorin 
levels than matrices from untreated CAFs. Nevertheless, 
no significant quantitative differences in adhesion were 
noted between the various matrices, although cancer 
cells displayed a distinct ‘track-like’ spreading pattern 
when seeded on matrices from TGF-β1-treated CAFs. 
We surmise that decorin is part of a stromal barrier, 
preventing cancer cell spreading and thus invasion. 
Consequently, neoplastic cells need to modulate the ECM 
composition to overcome this stromal barrier and to create 
an invasion-permissive stroma. Such modulations can 
exist of paracrine regulation of ECM protein expression, 
which includes downregulation of decorin expression and 
upregulation of versican, biglycan and type I collagen.
We are aware that other mechanisms may contribute 
as well [2]. In our study we omitted to address enzymatic 
remodeling of the stroma. Hawinkels et al. described that 
cancer cell derived TGF-β1 turns fibroblasts into α-SMA-
positive CAFs that produce matrix metalloproteinases 
(MMP) [34]. Release of MMP in the stromal compartment 
could contribute to the breakdown of anti-adhesive 
proteoglycans like decorin. According to Imai et al., 
decorin contains cleavage sites for MMP-2 (gelatinase-A), 
MMP-3 (stromelysin-1) and MMP-7 (matrilysin) [35]. 
Gene expression profiling revealed that transition of in 
situ to invasive breast cancer was characterized by an 
increased expression of MMP in the stroma [4-6]. Other 
protease classes, suchs as cathepsins, may digest decorin 
as well [17, 36]. Proteolytic activity is also required to 
activate TGF-β1, since this cytokine is secreted as a latent 
molecule and sequestered by several ECM components. 
The ECM acts as a reservoir for cytokines, and decorin 
is able to bind TGF-β1 [37]. Proteolytic degradation of 
decorin results in release of this sequestered TGF-β1 [35].
TGF-β1 is an attractive candidate for targeted 
therapy, as this might prevent extensive stromal alterations 
during cancer progression. Lifetime exposure to a TGF-β 
antagonist protected mice against metastasis without 
adverse side effects [38]. According to Liu et al., TGF-β 
blockade in orthotopic mammary carcinoma mouse 
models significantly reduced tumor growth and metastasis 
[39]. Interestingly, this TGF-β blockade decreased the type 
I collagen content, which contributed to normalization of 
the tumor stroma and improved intratumoral penetration 
of therapeutics [39]. Further elucidation of ECM changes 
and their role in cancer progression is warranted. Naba et 
al. developed a proteomic strategy to determine the in vivo 
ECM composition of tumors and normal tissues [40]. Such 
a characterization of the ‘matrisome’ revealed that tumor- 
and stroma-derived ECM components differ among 
tumors with different metastatic potential [40]. This new 
strategy offers perspectives for future ECM analysis.
In conclusion, preinvasive tumoral lesions may 
shape the composition of the adjacent ECM through 
TGF-β1 release to secure an invasion-permissive 
microenvironment. Versican may be a more robust 
CAF-marker than α-SMA, although further research is 
warranted. Additional investigations on larger patient 
cohorts are required to elucidate the ability of altered 
stromal protein expression as prognostic marker in breast 




Cell culture and conditioned medium
Telomerase-immortalized human colon cancer-
associated fibroblasts (CAFs) were maintained in 
Dulbecco’s minimal essential medium (DMEM), 
supplemented with 10% fetal calf serum (FCS), 100 
U/ml penicillin, 100 µg/ml streptomycin and 2.5 µg/
ml fungizone (Life Technologies, Ghent, Belgium). 
Isolation and characterization of the CAFs was previously 
described [41]. Experiments were performed with human 
breast cancer cell lines BT474, MCF-7, MDA-MB-231, 
MDA-MB-453, SKBR3 and T47D, and human colorectal 
cancer cell lines CaCo-2, HCT8/E11, HT-29 and SW480. 
All cell lines were grown in DMEM supplemented with 
10% FCS, fungizone and antibiotics, except CaCo-2 cells 
(additionally supplemented with 5 µg/ml transferrin and 
1% MEM-NEAA or non-essential amino acids solution; 
Life Technologies), and HT-29 (McCoy’s medium 
supplemented with antibiotics, fungizone and 10% 
FCS; Life Technologies). Serum-free 10x concentrated 
conditioned medium (CM) derived from 3x107 cancer 
cells was obtained after 24h of incubation and prepared 
as previously described [41]. HEK-293-EBNA-DCN cells 
(kindly provided by dr. Ake Oldberg, Lund University, 
Sweden) were cultured in DMEM supplemented with 
10% FCS, antibiotics and fungizone, and 100 µg/ml 
hygromycin B (Life Technologies) for selection [42]. CM 
from HEK-293-EBNA-DCN cells containing His-tagged 
human recombinant decorin was collected after 48h of 
incubation and 10x concentrated with Centricon Plus-70 
centrifugal filters (Merck Millipore, Overijse, Belgium). 
Concentrated CM was stored at -20°C until decorin 
purification.
Reagents and experimental set-up
The following human recombinant proteins were 
used: bFGF (PeproTech EC, London, UK), EGF, TGF-α 
(both by Sigma-Aldrich, St Louis, MO, USA), IGF-1, IL-
6, IL-8, NRG-β1, OSM, TGF-β1 and TNF-α1 (all by R&D 
Systems, Minneapolis, MN, USA). CAFs were grown in 
T-25 tissue culture flasks and treatment with cytokines (in 
the presence of 10% FCS) or CM (in the presence of 5% 
FCS) started when 95% confluence was reached. Medium 
was changed every 48h. After 6 days of treatment, cell 
lysates or RNA samples were prepared.
Cell lysates, SDS-PAGE and Western blots
CAFs were harvested in Laemmli lysis buffer (0.125 
M Tris-HCl, 10% glycerol, 2.3% sodium dodecyl sulfate 
(SDS), pH 6.8). Lysates were suspended in reducing 
sample buffer (0.5 M Tris-HCl, 40% glycerol, 9.2% SDS, 
4.5% 2-mercaptoethanol, 0.011% bromophenolblue, 
pH 6.8) and boiled at 95°C for 5 minutes. Equal protein 
amounts were separated on 8% polyacrylamide gels, 
transferred to nitrocellulose membranes (Bio-Rad, 
Hercules, CA, USA), blocked in 5% nonfat milk in 
phosphate-buffered saline (PBS) with 0.5% Tween-20 
(Sigma-Aldrich), and immunostained. The following 
antibodies were used: anti-α Smooth Muscle Actin 
(SMA, clone 1A4, Sigma-Aldrich), anti-biglycan (H-
150, SantaCruzBiotechnology, Santa Cruz, CA, USA), 
anti-decorin (clone 115402, R&D Systems), anti-
versican (H-56, SantaCruz Biotechnology). Detection 
was performed by horseradish peroxidase-conjugated 
secondary antibodies (all GE Healthcare, Pittsburgh, 
PA, USA) and chemiluminescence (Pierce ECL Western 
blotting substrate, Thermo Scientific, Rockford, IL, USA) 
according to the manufacturer’s instructions. Membranes 
were stripped with ReBlot Plus mild antibody stripping 
solution (Merck Millipore) and reprobed with anti-α-
tubulin (clone B-5-1-2, Sigma-Aldrich) as a loading 
control. Quantification of protein expression was 
performed with ImageJ software (NIH, MD, USA).
RNA-isolation and RT-qPCR analysis
CAFs were trypsinized and cell pellets were washed 
twice with RNase-free water. RNA was isolated with the 
miRNeasy kit (Qiagen, Venlo, The Netherlands), cDNA 
synthesis was performed with the iScript cDNA synthesis 
kit (Bio-Rad), and RT-qPCR analysis was performed 
on the MyiQ RT-PCR detection system (Bio-Rad) by 
using Mesa Green qPCR MasterMix Plus (Eurogentec, 
Seraing, Belgium), in accordance with the manufacturer’s 
instructions. A preliminary experiment was conducted to 
identify three appropriate reference genes (TBP, YWHAZ, 
GAPDH) out of a set of ten genes by using qBASE+ 
software (Biogazelle, Zwijnaarde, Belgium). Primers 
(Biolegio, Nijmegen, The Netherlands) are displayed in 
Table 1. All primers were blasted in Primer Blast (NCBI).
Immunohistochemistry (IHC)
Twenty specimens were selected out of a DCIS 
cohort diagnosed at Ghent University Hospital between 
1 January 2007 and 31 December 2011, with approval 
of the local ethics committee. Selection was based on 
stromal architecture and availability of formalin-fixed, 
paraffin-embedded (FFPE) tissue blocks. IHC for decorin 
and α-SMA has previously been performed [11]. IHC for 
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versican (dilution 1/25, HPA004726, Atlas Antibodies, 
Stockholm, Sweden) and biglycan (dilution 1/200, 
HPA003157, Atlas Antibodies) was performed on 3.5 µm 
FFPE tissue sections, using a Ventana Automated Slide 
Stainer (Benchmark XT, Ventana Medical Systems, AZ, 
USA). Heat-induced epitope retrieval was carried out 
using CC2 (Ventana Medical Systems). Visualization was 
achieved with the ultraViewTM Universal DAB Detection 
Kit (Ventana Medical Systems). Optimal dilutions and 
conditions were initially determined by IHC on placenta 
tissue (biglycan) and cerebral cortex (versican). Stromal 
expression was scored semi-quantitatively as low (or low 
to moderate) or high. Versican IHC of one DCIS case 
was not assessable because of tissue exhaustion; nineteen 
DCIS remained for evaluation.
Purification of decorin
His-tagged human recombinant decorin was purified 
from 10x concentrated CM from HEK-293-EBNA-DCN 
cells. CM was adjusted to 20 mM Tris and 300 mM NaCl 
(pH 8.0) with stock solutions and incubated with Ni2+-
NTA agarose beads (Qiagen) at 4°C for 1h with agitation. 
Beads were collected by centrifugation and washed five 
times (mild centrifugation at 4°C) with wash buffer (20 
mM Tris and 300 mM NaCl). Supernatant was disgarded. 
Recombinant decorin was eluted by adding elution buffer 
(20 mM Tris, 300 mM NaCl, 300 mM imidazole, pH 7.5). 
Supernatans was collected (mild centrifugation at 4°C) 
and 10x concentrated with 3K centrifugal filters (Merck 
Millipore). The concentrate was then diluted in excess 
PBS and concentrated again to wash away remaining 
imidazole. Decorin concentration was determined by 
using a spectrophotometer. Samples were passed through 
a 0.2µm Whatman filter before storage at -20° until further 
use.
Coating assays
For single reagent assays, 96-well plates were 
incubated overnight at 37°C with type I collagen or 
purified decorin in PBS. For combined coating assays, 
96-well plates were incubated 1h with type I collagen (rat 
tail, SantaCruz) in PBS and washed once with PBS, before 
overnight incubation with purified decorin in PBS at 37°C. 
Wells were washed once with PBS to remove excess of 
unbound proteins, before seeding cancer cells onto the 
coatings (10.000 cells/well). After 24h of incubation at 
37° in a 5% CO
2
 incubator, SRB and MTT assays were 
performed.
MTT
Culture medium of 96-well plates was replaced 
by 100 µl culture medium containing 1mg/ml MTT. 
Following 2h incubation at 37°C, MTT-containing medium 
was removed and 150 µl of dimethylsulfoxide (DMSO) 
was added to dissolve formazan crystals. Absorbance was 
measured at 570 nm with a spectrophotometer (Paradigm, 
Molecular Devices, USA).
SRB
Culture medium of 96-well plates was removed 
and cells were fixed with 50 µl 50% trichloroacetic acid 
solution for 1h. Plates were washed 5 times with water. 
After air drying, 50 µl of 0.4% SRB in 1% acetic acid 
solution was added to each well and incubated for 30 
minutes at 4°C. After SRB removal, plates were washed 
5 times with 1% acetic acid before air drying. Bound 
SRB was solubilized with 200 µl 10 mM Tris buffer 
(pH 10.5). Absorbance was measured at 570 nm with a 
spectrophotometer (Paradigm, Molecular Devices, USA).
Table 1: Forward and reverse primer sequences for RT-qPCR analysis of mRNA expression














Production of CAF-derived matrices
CAF-derived matrices were generated according 
to an adaptation of the protocol of Castello-Cros et al. 
for preparation of fibroblast-derived matrices in 96-well 
(10.000 cells/well) and 6-well (300.000 cells/well) culture 
plates [18]. Cell spreading was quantified by assessing the 
factor shape (i.e. inverse circularity or P2/4πA) in Adobe 
Photoshop CX5 software (Adobe Systems Incorporated, 
San Jose, CA, USA).
Cell-electrode impedance attachment assay
Real-time monitoring of cell adhesion was assessed 
by an electrical impedance assay with an xCELLigence 
RTCA SP real-time cell-sensing device (ACEA 
Biosciences, San Diego, CA, USA). E-plates (ACEA 
Biosciences) were coated in quadruplicate with 10 µg/ml 
decorin, 10 µg/ml type I collagen or both (as described 
under coating assays). CaCo-2 and BT474 cells (10.000/
well) were seeded into coated E-plates and impedance 
was measured every 3 minutes for 24h. All assays were 
performed twice. Adhesion was expressed as the cell 
index, i.e. the change in electrical impedance at each time 
point (mean ± SD). Slopes for each curve were calculated.
Statistics
Statistical analysis was performed in IBM SPSS 
21.0 (SPSS, Chicago, IL, USA). Differences in cell 
adhesion on coatings were assessed by one-way ANOVA 
for SRB and MTT assays, and by Mann-Whitney U test 
on calculated slopes for electrical impedance assays. 
Differences in IHC staining between sclerotic and myxoid 
DCIS were analyzed using Fisher’s exact test. Differences 
in factor shape were assessed using Mann-Whitney U 
test. All mentioned tests were two-sided, and p<0.05 
was considered to be statistically significant. Power of 
IHC was calculated in SAS Power & Sample Size (SAS 
Institute, Cary, NC, USA).
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ACTA2: alpha smooth muscle actin
ASPN: asporin




COL1A1: type 1 collagen alpha-1
DCIS: ductal carcinoma in situ
DCN: decorin
DMEM: Dulbecco’s minimal essential medium
DMSO: dimethylsulfoxide 
ECM: extracellular matrix 
EGF: epidermal growth factor 
FCS: fetal calf serum
FFPE: formalin-fixed, paraffin-embedded
FMOD: fibromodulin
IDC: invasive ductal carcinoma




MMP : matrix metalloproteinase
MTT: 3-(4,5-dimethylthiazol-2yl)-5,5-diphenyl- 
tetrazolium bromide




PBS : phosphate-buffered saline
RT-qPCR : real time quantitative polymerase chain 
reaction
SD: standard deviation
SDS: sodium dodecyl sulfate
SLRP: small leucin-rich proteoglycans
SMA: smooth muscle actin
SRB: sulforhodamine B
TGF: transforming growth factor
TNF: tumor necrosis factor 
VCAN: versican
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